Roche – HealthQuill

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

by HealthQuill
November 26, 2024
0 Comments

Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future climate-related health threats, according to a statement from the University of Glasgow.

Climate Health Pharma

European body to teach medical students health risks from climate change

Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future.

by HealthQuill
October 16, 2024
0 Comments

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.

Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

by HealthQuill
July 4, 2024
0 Comments

Switzerland’s healthcare company, Roche, signed a pact with US-based Alnylam to jointly develop and commercialize a therapy to treat hypertension in people with high cardiovascular risk.

Drugs Health Pharma

Roche, Alnylam to jointly develop hypertension therapy

HQ Team July 25, 2023: Switzerland’s healthcare company, Roche, signed a pact with US-based Alnylam to jointly develop and commercialize a therapy to.